查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930994

罗库溴铵原料药市场按产品类型、应用、最终用户和给药途径划分，全球预测（2026-2032年）

Rocuronium Bromide API Market by Product Type, Application, End User, Route Of Administration - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年罗库溴铵原料药市场价值为 3.6547 亿美元，预计到 2026 年将成长至 3.8721 亿美元，预计到 2032 年将达到 5.5545 亿美元，复合年增长率为 6.16%。

关键市场统计数据
基准年 2025 3.6547亿美元
预计年份：2026年 3.8721亿美元
预测年份 2032 5.5545亿美元
复合年增长率 (%) 6.16%

策略性介绍概述了影响罗库溴铵原料药决策的临床效用、生产复杂性和采购需求。

罗库溴铵是一种重要的神经肌肉阻断剂，广泛应用于重症监护和外科手术护理链中，其药理特性使其适用于多种围手术全期和重症监护应用。本执行摘要的引言部分整体情况了该原料药，重点介绍了其临床效用、供应链趋势、生产复杂性、监管介面以及影响采购和临床应用的竞争格局。初步分析着重探讨了品牌罗库溴铵和非专利药之间的差异如何影响筹资策略、品质保证重点以及处方集决策。

不断发展的临床通讯协定、生产製造现代化、日益严格的监管以及地缘政治贸易波动正在重新定义原料药的供应和筹资策略。

罗库溴铵原料药的市场环境正经历多重变革，重塑生产者、供应商和临床相关人员的策略重点。其中一个重要的转折点源自于临床通讯协定的演变。加护病房的实践，特别是危重症监护程序和对人工呼吸器的日益依赖，推动了对神经肌肉阻断剂和定量注射剂的需求持续增长。同时，心血管、一般外科和整形外科手术室的发展趋势促使采购部门重新评估其库存策略以及品牌药与非专利药的选择，因为人们对互换性、稳定性和供应连续性的看法存在差异。

2025年关税调整对原料药价值链筹资策略、到岸成本趋势及供应链韧性的累积影响

2025年实施的关税及更广泛的贸易政策调整，显着增加了罗库溴铵等高无菌活性药物成分（API）的采购和生产成本结构的复杂性。关税引发的变化迫使许多相关人员重新评估其供应区域，进行到岸成本敏感度分析，并评估近岸外包或区域生产中心的可行性。为此，许多公司采取了双重采购策略和长期合同，以降低进口港口成本突然上涨和海关延误的风险。

深度細項分析揭示了产品类型、应用、最终用户需求和管理途径如何相互交织，从而塑造策略重点。

细分市场分析揭示了每种产品类型、应用、最终用户和给药途径的独特需求驱动因素，进而为每种产品类型製定专门的商业和营运策略提供依据。从产品类型观点，品牌罗库溴铵通常与注重品牌特定稳定性数据、製造商保固支援和优先供应商地位的高端采购管道相契合。另一方面，非专利罗库溴铵则吸引着重成本的买家和大型集团采购组织，他们更重视互换性和合约定价。就应用而言，加护病房(ICU) 的使用主要集中在人工呼吸器支持环境中，在这些环境中，可预测的起效时间和持续的神经肌肉阻断至关重要。同时，手术室的需求主要来自心血管、一般外科和整形外科手术的需求，这些手术优先考虑快速起效和可调节持续时间。

美洲、欧洲、中东和非洲以及亚太地区的区域监管复杂性和医疗保健基础设施发展趋势如何影响个人化的供应和打入市场策略

区域趋势呈现出清晰的策略重点和法规环境，供应商和临床相关人员必须对此予以关注。在美洲，医疗保健系统高度重视一体化采购机制、健全的药品监测报告和高水准的GMP认证，这影响供应商的选择以及加快监管申报的需求。在欧洲、中东和非洲地区，法规结构和采购机制呈现分化趋势。有些市场优先考虑集中竞标和严格的品质检验，而有些市场则需要适应性强的分销模式，以兼顾当地公立和私立医院的采购管道。

深入了解製造卓越性、监管前瞻性和服务导向供应模式如何定义原料药的领导地位。

罗库溴铵原料药领域的竞争优势源于规模化生产能力、良好的法规遵循记录以及为临床和商业相关人员提供可靠的文件和服务的能力。主导企业强调检验的无菌生产设施、全面的杂质分析以及完善的变更控制记录，从而降低采购方的风险并促进产品被纳入医院处方集。策略联盟、契约製造协议和许可协议十分常见，这些协议使企业能够拓展地域覆盖范围，提高应对力，同时保持品管。

製造商、供应商和临床采购团队可以采取哪些切实可行的步骤来增强原料药价值链的韧性、监管准备和市场适用性？

产业领导者应采取一系列切实有效、影响深远的倡议，以增强供应链韧性、合规性和市场应对力。首先，製造商应优先投资于经过验证的无菌生产能力和严格的杂质调查方法，这能直接降低检验风险并增强买家信心。其次，企业应采用双重采购或地理分散的供应商策略，以降低关税波动和物流中断带来的风险，同时透过统一的批次放行程序和相互审核框架来维持必要的品质监管。

本分析的研究方法采用混合方法，结合对主要相关人员的访谈、二手监管和临床文献以及严格的检验，以确保研究结果具有可操作性和检验。

本分析的调查方法结合了访谈、文献综述和结构化检验，以确保研究结果的可靠性和检验。访谈包括对来自不同地域和临床环境的生产经理、法规事务专业人员、医院药房主任和采购人员进行深度访谈，以获取有关营运挑战、合约行为和临床偏好的第一手资料。文献回顾涵盖了监管指导文件、药典标准、关于神经肌肉阻断剂使用的同行评审临床文献以及生产最佳实践指南，以对主要研究结果进行背景分析。

简要概述临床需求、监管压力以及对供应弹性的需求，这些因素将决定原料药市场的未来成功。

总之，罗库溴铵原料药市场格局的特点是不断变化的临床需求、日益严格的监管以及供应链的调整相互作用。品牌药与非专利药之间的区别、不同的临床环境（加护病房的重症监护和人工呼吸器管理与手术室的心血管、普通外科和整形外科手术）、多样化的终端用户运营模式（门诊手术中心、诊所和医院）以及持续输注和静脉大剂量投药之间的技术差异，共同构成了生产商和采购商面临的一系列复杂问题。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 罗库溴铵原料药市场（依产品类型划分）

  • 罗库溴铵（商品名）
  • 非专利罗库溴铵

9. 罗库溴铵原料药市场依应用领域划分

  • 加护病房
    • 重症监护治疗
    • 人工呼吸呼吸系统护理
  • 手术室
    • 心血管外科
    • 一般外科
    • 整形外科手术

第十章 罗库溴铵原料药市场（依最终用户划分）

  • 门诊手术中心
    • 普通外科中心
    • 整形外科中心
  • 诊所
    • 日间诊所
    • 专科诊所
  • 医院
    • 私立医院
    • 公立医院

11. 罗库溴铵原料药市场依给药途径划分

  • 持续输注
    • 控制注射
  • 静脉注射
    • Bolus注

12. 罗库溴铵原料药市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 罗库溴铵原料药市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国罗库溴铵原料药市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国：罗库溴铵原料药市场

16. 中国：罗库溴铵原料药市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aurobindo Pharma
  • Changzhou Comwin Fine Chemicals Co., Ltd
  • Curia（formerly AMRI）
  • Dr. Reddy's Laboratories Ltd.
  • Euticals
  • Fresenius Kabi AG
  • Global Calcium
  • Hikma Pharmaceuticals PLC
  • Jiangsu Run'an Pharmaceutical Co., Ltd.
  • Jiangxi Bioman Pharma Limited
  • Jubilant Life Sciences Ltd.
  • Lupin Ltd.
  • Pfizer Inc.
  • Reliance Life Sciences Private Limited
  • Sandoz International GmbH
  • Shaoxing Hantai Pharma
  • Synnat Pharma Private Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zhejiang Xianju
Product Code: MRR-7B550E008CDF

The Rocuronium Bromide API Market was valued at USD 365.47 million in 2025 and is projected to grow to USD 387.21 million in 2026, with a CAGR of 6.16%, reaching USD 555.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 365.47 million
Estimated Year [2026] USD 387.21 million
Forecast Year [2032] USD 555.45 million
CAGR (%) 6.16%

A strategic introduction that frames clinical utility, manufacturing complexity, and procurement imperatives shaping Rocuronium Bromide API decision-making

Rocuronium bromide remains a cornerstone neuromuscular blocking agent used across critical care and surgical pathways, with its pharmacologic profile underpinning a wide range of perioperative and intensive care applications. The introduction of this executive summary frames the API landscape by clarifying clinical utility, supply chain dynamics, manufacturing complexities, regulatory touchpoints, and the competitive contours that influence procurement and clinical adoption. In the opening analysis, emphasis is placed on how product type distinctions-between branded rocuronium bromide and generic rocuronium bromide-inform sourcing strategies, quality assurance priorities, and formulary decisions.

Transitioning from the clinical backdrop to supply-side mechanics, attention is given to differences in formulation pathways and the implications of route-of-administration modalities such as continuous infusion and intravenous injection on API specifications and packaging requirements. The introduction also signals the importance of end-user segmentation; where ambulatory surgery centers, clinics, and hospitals each impose distinct demand patterns, inventory turn dynamics, and regulatory compliance obligations. Finally, this section sets expectations for the report's analytical arc: identifying transformative shifts, assessing tariff impacts, extracting actionable segmentation intelligence, and offering concise recommendations for manufacturers, distributors, and clinical procurement teams seeking to navigate an evolving global environment.

How evolving clinical protocols, manufacturing modernization, regulatory tightening, and geopolitical trade shifts are redefining supply and sourcing strategies for the API

The landscape for Rocuronium Bromide API is experiencing several transformative shifts that are reshaping strategic priorities for manufacturers, suppliers, and clinical stakeholders. One major inflection stems from evolving clinical protocols where intensive care unit practices, notably critical care procedures and the increased reliance on mechanical ventilation, have elevated continuous demand for neuromuscular blocking agents and driven demand for controlled infusion-ready formulations. Concurrently, operating room dynamics across cardiovascular surgery, general surgery, and orthopedic surgery are prompting procurement groups to reassess stock strategies and product selection between branded and generic options, given differing perceptions of interchangeability, stability, and supply continuity.

On the supply side, manufacturing modernization and capacity rationalization are compelling API producers to accelerate investments in sterile facilities, stringent quality management systems, and validated cold chain logistics for intravenous formulations. Regulatory scrutiny continues to intensify, with authorities emphasizing batch traceability, impurity profiling, and post-approval change management, which in turn encourages vertically integrated strategies or long-term supply agreements. Geopolitical and trade developments are also reorienting sourcing strategies, prompting regional diversification of supply bases and a re-evaluation of reliance on single-source suppliers. Taken together, these shifts underscore a move from transactional procurement toward partnership-oriented supply models, where clinical outcomes, regulatory resilience, and manufacturing robustness are prioritized over short-term price competition.

The cumulative effects of 2025 tariff adjustments on sourcing strategies, landed cost dynamics, and supply chain resilience across the API value chain

The imposition of tariffs and broader trade policy adjustments in 2025 has introduced measurable complexity into procurement and manufacturing cost frameworks for advanced sterile APIs like rocuronium bromide. Tariff-driven changes have prompted many stakeholders to reassess supplier geographies, to conduct sensitivity analyses on landed cost, and to evaluate the feasibility of nearshoring or regional production hubs. In response, a range of companies have pursued dual-sourcing strategies and longer-term contracting to mitigate exposure to sudden cost escalations and clearance delays at ports of entry.

Moreover, tariffs have altered supplier negotiation dynamics, incentivizing manufacturers to explore cost efficiencies in their downstream processes such as secondary packaging, labeling localization, and logistic consolidation to preserve margins without degrading quality or compliance. Regulatory filings and import documentation have gained increased importance as customs scrutiny intensifies, and firms are investing in tariff classification expertise and supply chain compliance teams to reduce clearance friction. Financial planning across procurement and manufacturing has shifted toward scenario modeling and hedging strategies, with organizations prioritizing supply continuity and regulatory alignment over opportunistic cost savings. These cumulative impacts are accelerating structural responses across the value chain, encouraging strategic realignment that balances clinical reliability, regulatory compliance, and resilient sourcing against the persistent realities of changing trade policy.

Deep segmentation insights revealing how product type, application, end-user requirements, and administration route intersect to shape strategic priorities

Segmentation analysis reveals differentiated demand drivers that inform targeted commercial and operational strategies across product types, applications, end users, and administration routes. When viewed through the lens of product type, branded rocuronium bromide typically aligns with premium procurement channels that emphasize brand-specific stability data, manufacturer-backed support, and preferred supplier status, whereas generic rocuronium bromide attracts cost-sensitive buyers and large group purchasing organizations focused on interchangeability and contract pricing. Regarding application, intensive care unit usage concentrates on critical care procedures and mechanical ventilation contexts where predictable onset and sustained neuromuscular blockade are operationally critical, while operating room demand is driven by cardiovascular surgery, general surgery, and orthopedic surgery needs that prioritize rapid onset and titratable duration.

End-user segmentation further differentiates demand where ambulatory surgery centers-comprising general surgery centers and orthopedic centers-tend to favor single-procedure packaging and rapid turnaround logistics. Clinics, including day clinics and specialty clinics, prioritize modest inventory holdings with flexible ordering options, and hospitals-both private and public-require scalable supply commitments, stringent quality documentation, and contingency planning. Route of administration segmentation underscores manufacturing and distribution implications: continuous infusion formulations that include controlled infusion modalities demand specific sterility assurance, accurate concentration labeling, and compatibility testing, while intravenous injection formats that utilize bolus injection approaches necessitate short-term stability data and immediate-use packaging. These interlocking segmentation dimensions guide product development, regulatory strategy, and commercial positioning by clarifying where clinical attributes, procurement behavior, and logistical constraints intersect.

How regional regulatory complexity and healthcare infrastructure trends across the Americas, Europe, Middle East & Africa, and Asia-Pacific dictate tailored supply and go-to-market strategies

Regional dynamics show distinct strategic priorities and regulatory environments that must be addressed by suppliers and clinical stakeholders. In the Americas, health systems emphasize consolidated purchasing mechanisms, robust pharmacovigilance reporting, and high standards for good manufacturing practice certifications, which influences supplier selection and the imperative for rapid regulatory dossiers. Transitioning to Europe, Middle East & Africa, stakeholders encounter a mosaic of regulatory frameworks and procurement mechanisms; while some markets prioritize centralized tenders and stringent quality validation, others require adaptive distribution models that account for local public and private hospital procurement channels.

Across Asia-Pacific, demand patterns are influenced by heterogeneous healthcare infrastructure, with certain markets demonstrating rapid growth in ambulatory surgical capacity and others prioritizing public hospital modernization. This regional diversity necessitates differentiated go-to-market approaches: tailored regulatory submissions, localized technical documentation, and distribution partnerships that reconcile central regulatory approvals with decentralized purchasing behaviors. Consequently, manufacturers and distributors must align manufacturing footprints, logistic pathways, and regulatory liaison capabilities with the particular operational realities of the Americas, Europe, Middle East & Africa, and Asia-Pacific to ensure timely supply and adherence to clinical and compliance expectations.

Competitive and operational intelligence on how manufacturing excellence, regulatory foresight, and service-oriented supply models determine leadership in the API arena

Competitive dynamics within the Rocuronium Bromide API space are shaped by a combination of scale-driven manufacturing capabilities, regulatory track records, and the ability to support clinical and commercial stakeholders with reliable documentation and service. Leading-focused firms emphasize validated sterile manufacturing suites, comprehensive impurity profiling, and robust change-control histories that reduce buyer risk and facilitate hospital formulary acceptance. Strategic partnerships, contract manufacturing arrangements, and licensing agreements are common, enabling companies to extend geographic reach while preserving quality governance and responsiveness to local regulatory expectations.

Innovation in manufacturing processes-such as improved synthetic routes that reduce impurity burdens or investments in closed-system filling technologies-serves as a meaningful competitive differentiator. Additionally, some players are investing in supply-chain transparency initiatives, serialization, and batch-level traceability to address increasing regulator and purchaser demand for auditability. For buyers, the ability of suppliers to provide clinical support, educational materials, and post-market surveillance collaboration factors heavily into contracting decisions. In sum, companies that combine manufacturing excellence with regulatory foresight and customer-centric service models are best positioned to capture longer-term partnerships across diverse clinical settings.

Actionable steps for manufacturers, suppliers, and clinical procurement teams to enhance resilience, regulatory preparedness, and market alignment in the API value chain

Industry leaders should pursue a set of pragmatic, high-impact actions to strengthen supply resilience, regulatory compliance, and market responsiveness. First, manufacturers should prioritize investments in validated sterile production capacity and rigorous impurity control methodologies that directly reduce regulatory risk and enhance buyer confidence. Second, firms should adopt dual-sourcing or geographically diversified supplier strategies to mitigate exposure to tariff volatility and logistical disruptions, while maintaining the necessary quality oversight through harmonized batch release procedures and reciprocal audit frameworks.

Third, commercial teams must align product positioning to distinct segmentation needs by clearly articulating the value proposition for branded versus generic offerings and developing tailored support for the intensive care unit, operating room, ambulatory surgery center, clinic, and hospital environments. Fourth, organizations should streamline regulatory engagement by investing in comprehensive dossier readiness, scenario-based change management plans, and proactive pharmacovigilance collaborations with major end users. Finally, forging longer-term supply agreements, implementing flexible pricing mechanisms tied to volume and service tiers, and accelerating transparency measures such as serialization will collectively improve trust and reduce procurement friction. Taken together, these recommendations enable both upstream and downstream stakeholders to translate analytical insight into operationally resilient outcomes.

A mixed-methods research approach combining primary stakeholder interviews, secondary regulatory and clinical literature, and rigorous triangulation to ensure actionable and validated findings

The research methodology underpinning this analysis combines primary interviews, secondary literature synthesis, and structured triangulation to ensure robust, verifiable findings. Primary engagement included in-depth interviews with manufacturing leads, regulatory affairs specialists, hospital pharmacy directors, and procurement executives across a range of geographies and clinical settings, enabling direct insight into operational pain points, contracting behaviors, and clinical preferences. Secondary research encompassed regulatory guidance documents, pharmacopoeial standards, peer-reviewed clinical literature regarding neuromuscular blocking agent usage, and manufacturing best-practice guidelines to contextualize primary inputs.

Analytical processes applied cross-validation techniques to reconcile divergent viewpoints and to isolate consistent themes relevant to product type differentiation, application-specific requirements, end-user behaviors, and route-of-administration implications. The methodology emphasized transparency in evidence linkage and clearly documented assumptions for any interpretive judgments made during synthesis. Quality control measures included peer review of key findings and iterative validation with domain experts to ensure accuracy and practical relevance for decision-makers. Overall, this mixed-method approach supports a balanced, evidence-driven perspective intended to inform strategic planning and operational adjustments across the Rocuronium Bromide API ecosystem.

A concise conclusion synthesizing clinical demand, regulatory pressures, and supply resilience imperatives that determine future success in the API market

In conclusion, the Rocuronium Bromide API landscape is characterized by an interplay of clinical demand evolution, regulatory intensification, and supply-chain recalibration. The distinctions between branded and generic product types; the divergent clinical contexts spanning intensive care unit critical care procedures and mechanical ventilation versus operating room cardiovascular, general, and orthopedic surgery; the variety of end-user operational models across ambulatory surgery centers, clinics, and hospitals; and the technical implications of continuous infusion and intravenous bolus administration together create a multifaceted set of priorities for manufacturers and purchasers.

Responding effectively requires integrated strategies that marry manufacturing quality and capacity planning with tailored commercial models and proactive regulatory engagement. As trade policy and tariff shifts continue to influence landed cost and sourcing decisions, resilience will depend on geographic diversification, contractual flexibility, and investments in compliance capabilities. Ultimately, the organizations that translate this analysis into focused operational changes-by strengthening sterile manufacturing, deepening customer collaboration, and anticipating regulatory expectations-will be best positioned to deliver reliable supply and clinical value in the years ahead.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rocuronium Bromide API Market, by Product Type

  • 8.1. Branded Rocuronium Bromide
  • 8.2. Generic Rocuronium Bromide

9. Rocuronium Bromide API Market, by Application

  • 9.1. Intensive Care Unit
    • 9.1.1. Critical Care Procedures
    • 9.1.2. Mechanical Ventilation
  • 9.2. Operating Room
    • 9.2.1. Cardiovascular Surgery
    • 9.2.2. General Surgery
    • 9.2.3. Orthopedic Surgery

10. Rocuronium Bromide API Market, by End User

  • 10.1. Ambulatory Surgery Centers
    • 10.1.1. General Surgery Centers
    • 10.1.2. Orthopedic Centers
  • 10.2. Clinics
    • 10.2.1. Day Clinics
    • 10.2.2. Specialty Clinics
  • 10.3. Hospitals
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals

11. Rocuronium Bromide API Market, by Route Of Administration

  • 11.1. Continuous Infusion
    • 11.1.1. Controlled Infusion
  • 11.2. Intravenous Injection
    • 11.2.1. Bolus Injection

12. Rocuronium Bromide API Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Rocuronium Bromide API Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rocuronium Bromide API Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Rocuronium Bromide API Market

16. China Rocuronium Bromide API Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aurobindo Pharma
  • 17.6. Changzhou Comwin Fine Chemicals Co., Ltd
  • 17.7. Curia (formerly AMRI)
  • 17.8. Dr. Reddy's Laboratories Ltd.
  • 17.9. Euticals
  • 17.10. Fresenius Kabi AG
  • 17.11. Global Calcium
  • 17.12. Hikma Pharmaceuticals PLC
  • 17.13. Jiangsu Run'an Pharmaceutical Co., Ltd.
  • 17.14. Jiangxi Bioman Pharma Limited
  • 17.15. Jubilant Life Sciences Ltd.
  • 17.16. Lupin Ltd.
  • 17.17. Pfizer Inc.
  • 17.18. Reliance Life Sciences Private Limited
  • 17.19. Sandoz International GmbH
  • 17.20. Shaoxing Hantai Pharma
  • 17.21. Synnat Pharma Private Limited
  • 17.22. Teva Pharmaceutical Industries Ltd.
  • 17.23. Viatris Inc.
  • 17.24. Zhejiang Xianju

LIST OF FIGURES

  • FIGURE 1. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ROCURONIUM BROMIDE API MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ROCURONIUM BROMIDE API MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ROCURONIUM BROMIDE API MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY BRANDED ROCURONIUM BROMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY BRANDED ROCURONIUM BROMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY BRANDED ROCURONIUM BROMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GENERIC ROCURONIUM BROMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GENERIC ROCURONIUM BROMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GENERIC ROCURONIUM BROMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CRITICAL CARE PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CRITICAL CARE PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CRITICAL CARE PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY ORTHOPEDIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY ORTHOPEDIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY ORTHOPEDIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GENERAL SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GENERAL SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GENERAL SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY ORTHOPEDIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY ORTHOPEDIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY ORTHOPEDIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY DAY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY DAY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY DAY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CONTROLLED INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CONTROLLED INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY CONTROLLED INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY BOLUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY BOLUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 244. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 246. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL ROCURONIUM BROMIDE API MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA ROCURONIUM BROMIDE API MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY INTENSIVE CARE UNIT, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY OPERATING ROOM, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY CONTINUOUS INFUSION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA ROCURONIUM BROMIDE API MARKET SIZE, BY INTRAVENOUS INJECTION, 2018-2032 (USD MILLION)